3 recruiting, 2 active not recruiting, 2 completed, 2 unknown. 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 3, Active not recruiting 2, Completed 2, Unknown 2, Not yet recruiting 1 |
Follow Pseudomyxoma Peritonei: new trials by email Literature Review of Pseudomyxoma Peritonei trials Research Report on Pseudomyxoma Peritonei
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE) Intestinal, Multivisceral or Modified Multivisceral Transplantation, Alemtuzumab, Tacrolimus - Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum | Phase 2 | Not yet recruiting | Case Comprehensive Cancer Center | 20 | 2026-11-01 | 2026-09-24 |
| Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms Metformin - Appendiceal Mucinous Neoplasm, Pseudomyxoma Peritonei | Phase 2 | Recruiting | University of California, Irvine | 15 | 2026-06-18 | 2026-07-13 |
| Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients Capecitabine 1250 mg/m2 /day - Cyclophosphamide 50Mg/day - Pseudomyxoma Peritonei | Phase 2 | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 31 | 2024-11-22 | 2025-01-30 |
| BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei Bromelain, Acetylcysteine, Interventional radiology insertion of drain - Pseudomyxoma Peritonei, Peritoneal Cancer | Phase 2 | Unknown | Mucpharm Pty Ltd | 62 | 2022-05-01 | 2022-03-15 |
| Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC Mitomycin C, flat dose 40 mg, Mitomycin C, weight-based dose 12.5 mg/m2 - Peritoneal Carcinomatosis | Phase 2 | Recruiting | Prakash Pandalai | 100 | 2021-06-04 | 2026-04-01 |
| Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients Capecitabine - Pseudomyxoma Peritonei | Phase 2 | Unknown | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 28 | 2018-12-03 | 2022-04-11 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin PrevPac (Prevacid, Amoxicillin, Clarithromycin) - Pseudomyxoma Peritonei, Appendiceal Neoplasms | Phase 2 | Active not recruiting | Mercy Medical Center | 80 | 2015-01-01 | 2024-11-19 |
| HIPEC Using High Intra-abdominal Pressure Cytoreductive surgery, Low Intra abdominal pressure HIPEC, High Intra abdominal pressure HIPEC - Pseudomyxoma Peritonei, Colorectal Cancer | Phase 2 | Completed | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 38 | 2014-12-01 | 2018-02-23 |
| HIPEC for Peritoneal Carcinomatosis HIPEC, Mitomycin C - Peritoneal Carcinomatosis, Colorectal Cancer | Phase 2 | Completed | Albert Einstein College of Medicine | 51 | 2011-11-01 | 2024-10-24 |
Appendiceal Neoplasms (3) · Colorectal Neoplasms (3) · Adenocarcinoma, Mucinous (2) · Peritoneal Neoplasms (2) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Adrenocortical Carcinoma (1) · Bile Duct Neoplasms (1) · Carcinoma, Acinar Cell (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Basal Cell (1) · Carcinoma, Endometrioid (1) · Carcinoma, Giant Cell (1) · Carcinoma, Transitional Cell (1) · Carcinosarcoma (1)
Adenocarcinoma (10) · Carcinoma (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Neoplasms, Glandular and Epithelial (10) · Neoplasms, Cystic, Mucinous, and Serous (9) · Adenocarcinoma, Mucinous (8) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Gastrointestinal Diseases (5) · Gastrointestinal Neoplasms (5) · Neoplasms by Site (5) · Intestinal Diseases (4) · Intestinal Neoplasms (4) · Cecal Diseases (3)
Capecitabine (2) · Mitomycin (2) · Acetylcysteine (1) · Alemtuzumab (1) · Amoxicillin (1) · Bromelains (1) · CTLA-4 Antigen (1) · Clarithromycin (1) · Cytoreduction Surgical Procedures (1) · Hyperthermic Intraperitoneal Chemotherapy (1) · Ipilimumab (1) · Lansoprazole (1) · Magnetic Resonance Spectroscopy (1) · Metformin (1) · Nivolumab (1)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (3) · Albert Einstein College of Medicine (1) · Case Comprehensive Cancer Center (1) · Mercy Medical Center (1) · Mucpharm Pty Ltd (1) · National Cancer Institute (NCI) (1) · Prakash Pandalai (1) · University of California, Irvine (1)
United States (6) · Italy (3) · Guam (1)
Alessandra Raimondi, MD (1) · Alvaro Arjona Sanchez, MD (1) · Armando Sardi, M.D. (1) · Armando Sardi, MD (1) · Edward Levine, MD (1) · Haroon Choudry, MD (1) · Ignace de Hingh, MD (1) · John McAuliffe, M.D. (1) · Maria Di Bartolomeo, MD (1) · Masato Fujiki, MD, PhD (1) · Oliver Eng, MD (1) · Prakash Pandalai, MD (1) · Sandip P Patel (1) · Scott Merrell, PhD (1) · Shigeki Kusamura, MD PhD (1)
PMID 31262599, PMID 31969335, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34716198, PMID 36410913, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790
U10CA180888 (1)